Gesgenéricos y OWL: M&A sector biotecnológico en Junio 2015

,
Integral service around a transaction
BY : Diego Gutiérrez16/07/2015
Las biotecnológicas extranjeras se interesan por las españolas. La empresa Gesgenéricos ha sido comprada por la Israelí Altan Pharma y además la vasca OWL ha concedido a Galmed una opción de compra de  hasta el 19,9 % de la compañía.

 

m&a sector biotecnología en Junio

Altan Pharma compra Gesgenéricos

 La irlandesa Altan Phrama entra en España con la adquisición del grupo farmacéutico GesGenéricos por un importe de €87,5M. “Para financiar la operación, Altan ha recibido 34,5M de la sociedad inversora Malin y un crédito del banco Santander” comenta Diego Gutiérrez de Abra –Invest.

Altan es una compañía farmacéutica que ha sido creada recientemente por cuatro profesionales provenientes de Abott Laboratories. La adquisición del grupo GES representa la realización del primer hito en el plan estratégico a largo plazo de Altan que quiere crear  una compañía de fármacos especializados global. La adquisición de GES va a permitir a Altan entrar en el sector de fármacos inyectables en Europa y mercados asiáticos y latinoamericanos selectos.

 GESGenéricos es un grupo de propiedad privada de compañías españolas  con sede en Madrid, que desarrolla, fabrica y comercializa fármacos inyectables especializados para el mercado hospitalario y de proveedores de atención sanitaria. GES ha estado ofreciendo al mercado español una línea completa de fármacos inyectables desde 1985.

OWL firma un acuerdo con Galmed Pharmaceuticals

La empresa biotecnológica vasca OWL, que lidera el mercado de  la utilización de la metabolómica para el desarrollo de diagnósticos de enfermedades hepáticas, ha anunciado un acuerdo de licencia e investigación y de opción de compra de participaciones con la Israelí Galmed Pharmaceuticals.

El acuerdo tiene como objetivo el desarrollo de un test no invasivo que incluirá una serie de biomarcadores metabolómicos únicos que predecirán potencialmente la respuesta terapéutica de Aramchol, tratamiento oral diario para el tratamiento de la Esteatohepatitis no alcóholica

 Además se ha formalizado un acuerdo para regular la participación de Galmed en el capital de OWL a través de la compra de acciones ligado a 2 hitos fundamentales del proyecto. El primer pago de €75,000 se realizará tras completar el interim análisis del estudio Arrest previsto para la primera mitad del 2016 y el segundo pago de €100.000 se realizará tras completar el estudio ARREST. La inversión prevista en OWL será de  €175,000, a la valoración más reciente de la compañía. Finalmente,  OWL ha concedido a Galmed una opción de compra de  hasta el 19,9 % de la compañía.

 

Si estas buscando financiación ponte en contacto con nosotros. A través del +34946024142 o rellenando el formulario de contacto.

The M&A Professionals

Meet our services

MEET
OUR
metodologY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
"Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu